The Latest in PTSD Treatment
Jul. 2, 2021 Psychology Today
Today, I’m writing from the cutting-edge of innovation and research in PTSD. PTSD science continues to advance exponentially, and exciting breakthroughs are on the horizon. What I’m presenting in this post are some of the highlights from the last two years of scientific findings.
While these approaches can’t yet be considered the gold standard for PTSD treatment, what they represent is hope for an ever-expanding array of options that might be available for sufferers one day.
I’ve divided the treatments into three categories: psychotropic medications, procedures, and non-pharmacological approaches.
May 2021 heralded promising results from the first phase 3 clinical trial testing MDMA-assisted psychotherapy for the treatment of PTSD. In MDMA-assisted therapy, the medication MDMA is only administered a few times, and the talk therapy component remains an integral part of this combination treatment.
In an article published in Nature Medicine, researchers from UCSF reported on results of their trial, which sought to test the efficacy and safety of MDMA-assisted therapy for the treatment of 90 patients with severe PTSD over 15 clinical sites. The results were impressive, with patients reporting a large drop in symptoms after receiving MDMA-assisted therapy.
Of particular interest was that the study included patients with common PTSD comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. In this way, the study conditions better mimicked real-world clinical scenarios and therefore gave cause to be optimistic that such a treatment may eventually provide tangible benefit to patients treated in clinical practice.
Another plus for this research is that, for the duration of this study, the researchers reported that MDMA did not induce adverse events such as abuse potential or suicidality. Furthermore, unlike most medications for mental illnesses which are often taken daily for a substantial length of time, MDMA is only taken a few times.
A second phase 3 trial is currently underway and, if results continue to be encouraging, a drug application with the FDA is anticipated in 2022.
Repeated Ketamine Infusions
Ketamine is a non-barbiturate anesthetic and antagonist at the NMDA receptor. It is typically administered intravenously and has been used for years to provide pain relief to patients with severe burns. It was in this use that its dissociative properties became apparent. Ketamine may disrupt the process by which traumatic memories are laid down, as some studies show that those who received ketamine after a traumatic event were less likely to go on to develop PTSD.
In a 2021 study published in the American Journal of Psychiatry (in Advance), researchers from Icahn School of Medicine at Mount Sinai suggested that repeated ketamine infusions may lead to rapid symptom improvement in people with PTSD.
Thirty study participants who received six ketamine infusions over a two-week period experienced greater drops in PTSD symptoms and comorbid depressive symptoms compared with participants who received the sedative midazolam, a psychoactive placebo control administered approximately three times a week for two weeks.
Side effects associated with the ketamine included blurred vision, dizziness, fatigue, and headache. Of more concern is that some participants did report dissociative symptoms that emerged during their ketamine infusions.
It’s important to note the limitations associated with ketamine: Benefits may last only a few weeks and there is a potential for patients getting addicted to this treatment.
Riluzole: A Glutamatergic Modulator
In a 2020 study published in the Journal of Clinical Psychiatry, researchers designed a randomized controlled trial that investigated the efficacy of Riluzole augmentation for combat-related PTSD symptoms resistant to treatment with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).
Riluzole is a neuroprotective drug that blocks glutamatergic neurotransmission in the CNS. Glutamate dysregulation has been implicated in the pathophysiology of PTSD, so medications that regulate brain glutamate concentrations may be an effective treatment strategy for PTSD.
Over a four-year period, veterans and active duty service members with combat-related PTSD who were not responsive to SSRI or SNRI pharmacotherapy were randomized to eight-week augmentation with a starting dose of 100 mg/day of riluzole or placebo.
An analysis of PTSD symptom clusters showed significantly greater improvement on PTSD hyperarousal symptoms in the riluzole group. However, Riluzole augmentation was not superior to placebo on change in depression, anxiety, or disability severity.
Stellate Ganglion Block Treatment
In 2008, media reports started to emerge about how a stellate ganglion block (SGB), an invasive manipulation of sympathetic nerve tissue, helped PTSD sufferers. The procedure, which consisted of injecting a local anesthetic into sympathetic nerve tissue in the neck, led to immediate symptom relief in a small group of patients.
Still, a positive outcome in a few cases is not sufficient to label something a treatment. A treatment should be more effective than a placebo, so it needs to be studied under controlled conditions. It took some time for the first controlled study of the SGB to be done, and the initial results, which were reported in 2016, were disappointing: The block was not superior to sham injection in relieving PTSD.
In early 2020, results of the first multisite, randomized clinical trial of (SGB) outcomes on PTSD symptoms were published in the Journal of the American Medical Association – Psychiatry and revealed reasons to not give up on SGB entirely. In this trial of active-duty service members with PTSD symptoms, the authors reported that two SGB treatments two weeks apart were effective in reducing PTSD scores over a period of eight weeks.